102 related articles for article (PubMed ID: 25347368)
1. Variant prostate carcinoma and elevated serum CA-125.
Bilen MA; Reyes A; Bhowmick D; Maa A; Bast R; Pisters LL; Lin SH; Logothetis CJ; Tu SM
Can J Urol; 2014 Oct; 21(5):7442-8. PubMed ID: 25347368
[TBL] [Abstract][Full Text] [Related]
2. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features.
Tu SM; Reyes A; Maa A; Bhowmick D; Pisters LL; Pettaway CA; Lin SH; Troncoso P; Logothetis CJ
Cancer; 2002 May; 94(10):2610-7. PubMed ID: 12173328
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China.
Pei XQ; He DL; Tian G; Lv W; Jiang YM; Wu DP; Fan JH; Wu KJ
Int Urol Nephrol; 2017 Apr; 49(4):629-635. PubMed ID: 28161841
[TBL] [Abstract][Full Text] [Related]
4. High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy.
Shigeta K; Kosaka T; Kitano S; Yasumizu Y; Miyazaki Y; Mizuno R; Shinojima T; Kikuchi E; Miyajima A; Tanoguchi H; Hasegawa S; Oya M
Ann Surg Oncol; 2016 Nov; 23(12):4115-4122. PubMed ID: 27364499
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.
Taplin ME; Armstrong AJ; Lin P; Krivoshik A; Phung D; Parli T; Tombal B; Beer TM
J Urol; 2017 Dec; 198(6):1324-1332. PubMed ID: 28736322
[TBL] [Abstract][Full Text] [Related]
6. Base of the skull metastases in metastatic castration-resistant prostate cancer.
Bourlon MT; Glodé LM; Crawford ED
Oncology (Williston Park); 2014 Dec; 28(12):1115-6, 1124. PubMed ID: 25510811
[No Abstract] [Full Text] [Related]
7. Clinical evaluation of carcinoembryonic and carbohydrate antigens as cancer biomarkers to monitor palliative chemotherapy in advanced stage gastric cancer.
Abbas M; Ahmed A; Khan GJ; Baig MMFA; Naveed M; Mikrani R; Cao T; Naeem S; Shi M; Dingding C
Curr Probl Cancer; 2019 Feb; 43(1):5-17. PubMed ID: 30172422
[TBL] [Abstract][Full Text] [Related]
8. Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis.
Han KS; Hong SJ
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1769-76. PubMed ID: 24858569
[TBL] [Abstract][Full Text] [Related]
9. Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer.
Jung J; Lee C; Lee C; Kwon T; You D; Jeong IG; Hong JH; Ahn H; Kim CS
Korean J Urol; 2015 Sep; 56(9):630-6. PubMed ID: 26366275
[TBL] [Abstract][Full Text] [Related]
10. Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer.
Shiota M; Kashiwagi E; Murakami T; Takeuchi A; Imada K; Inokuchi J; Tatsugami K; Eto M
Urol Oncol; 2019 Mar; 37(3):180.e19-180.e24. PubMed ID: 30446464
[TBL] [Abstract][Full Text] [Related]
11. Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer.
Jang HS; Koo KC; Cho KS; Chung BH
Yonsei Med J; 2016 Sep; 57(5):1070-8. PubMed ID: 27401636
[TBL] [Abstract][Full Text] [Related]
12. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.
Kobayashi K; Okuno N; Arai G; Nakatsu H; Maniwa A; Kamiya N; Satoh T; Kikukawa H; Nasu Y; Uemura H; Nakashima T; Mikami K; Iinuma M; Tanabe K; Furukawa J; Kobayashi H
Jpn J Clin Oncol; 2021 Apr; 51(4):544-551. PubMed ID: 33324967
[TBL] [Abstract][Full Text] [Related]
14. Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer.
Szarvas T; Sevcenco S; Módos O; Keresztes D; Nyirády P; Kubik A; Romics M; Kovalszky I; Reis H; Hadaschik B; Shariat SF; Kramer G
Urol Oncol; 2018 Jun; 36(6):312.e9-312.e15. PubMed ID: 29628317
[TBL] [Abstract][Full Text] [Related]
15. Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study.
Vaishampayan U; Shevrin D; Stein M; Heilbrun L; Land S; Stark K; Li J; Dickow B; Heath E; Smith D; Fontana J
Urology; 2015 Dec; 86(6):1206-11. PubMed ID: 26375845
[TBL] [Abstract][Full Text] [Related]
16. Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Han KS; Hong SJ
Yonsei Med J; 2015 Mar; 56(2):368-74. PubMed ID: 25683983
[TBL] [Abstract][Full Text] [Related]
17. The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.
Mahammedi H; Planchat E; Pouget M; Durando X; Curé H; Guy L; Van-Praagh I; Savareux L; Atger M; Bayet-Robert M; Gadea E; Abrial C; Thivat E; Chollet P; Eymard JC
Oncology; 2016; 90(2):69-78. PubMed ID: 26771576
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin analogs and disease control in castration-resistant prostate cancer: different biological behavior? Case series and review of the literature.
D'Angelillo RM; Greco C; Fiore M; Ippolito E; Eolo Trodella L; Iurato A; Molfese E; Ramella S; Trodella L
Tumori; 2014; 100(3):249-53. PubMed ID: 25076233
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509
[TBL] [Abstract][Full Text] [Related]
20. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
